(Q37967946)

26 August 2017

title

Certolizumab pegol for the treatment of rheumatoid arthritis (English)

1 reference

26 August 2017

1 reference

3

Paul Emery

0 references

author name string

Sarah Horton

series ordinal

1

1 reference

26 August 2017

Ceara Walsh

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

14 December 2011

1 reference

Expert Opinion on Biological Therapy

26 August 2017

number of pages

15

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

235-249

1 reference

Changes in the incidence and prevalence of rheumatoid arthritis in England and Wales, 1970-1982.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Measuring the impact of arthritis on worker productivity: perspectives, methodologic issues, and contextual factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

A 44-year-old woman with cutaneous bullae and extensive skin necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Rheumatoid arthritis: direct and indirect costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Measuring Worker Productivity: Frameworks and Measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.645533

10.1517/14712598.2012.645533

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1067588524

0 references

Fatcat ID

release_66ts5vulivfpdi3k3uh33zippi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/66ts5vulivfpdi3k3uh33zippi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference